# US 10,309,957 B2 · Method for determining sensitivity to fluorouracil in a subject having colorectal cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,309,957 B2
- Document ID: US10309957B2
- Status: Granted
- Kind: B2
- Application number: 15/708,178
- Filed: 2017-09-19
- Published: 2018-02-08
- Granted: 2019-06-04
- Earliest claimed: 2011-03-24
- Assignees: Keio University; Kabushiki Kaisha Yakult Honsha
- Applicants: Keio University; Kabushiki Kaisha Yakult Honsha
- Inventors: Yusuke Tanigawara; Akito Nishimuta; Yuki Otani; Mitsuhisa Matsuo
- Web page: https://patentgrep.com/patent/US10309957B2

## CPC

- G01N 33/5091: {for testing the pathological state of an organism}
- A61K 31/132: having two or more amino groups, e.g. spermidine, putrescine
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/282: Platinum compounds
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/515: Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/575: for cancer
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N 2800/7066: Metabolic pathways
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

To provide a marker for determining sensitivity to an anti-cancer agent, which can determine whether or not a patient has a therapeutic response to the anti-cancer agent, and cancer therapeutic means employing the marker.

## Claims

### Claim 1

A method for determining sensitivity of a subject to fluorouracil or a salt thereof, the method comprising:
administering fluorouracil or a salt thereof to a subject having colorectal cancer,
measuring a level of cysteine-glutathione in a specimen derived from the subject.

### Claim 2 (depends on 1)

The method of claim 1, further comprising comparing the level of cysteine-glutathione in the specimen to a standard, and administering fluorouracil or a salt thereof to the subject when the level of cysteine-glutathione in the specimen is the same or higher compared to the standard.